Table 1 Anti-tumor effects of aspirin in recent meta-analyses
Author (year) [reference] | Number of studies (number of patients) | Dose of aspirin (mg) | Type of cancer | Main findings |
|---|---|---|---|---|
González-Pérez et al. (2003) [13] | 4, 5 and 11 | Any | Esophageal, gastric and breast cancer | Aspirin reduced the incidence of esophageal cancer (RR 0·51, 95 % CI 0.38–0.69), gastric cancer (RR 0.73, 0.63–0.84) and breast cancer (RR 0.77, 0.69–0.86), derived from four, five and eleven studies respectively |
Flossmann et al. (2007) [12] | 2 (5061) | 300< | CRC | Aspirin reduced the incidence of CRC (HR 0.74, 95 % CI 0.56–0.97, p = 0.02) |
Rothwell et al. (2010) [6] | 5 | 75–300 | CRC | Low-dose aspirin reduced the 20-year incidence and mortality of CRC (incidence HR 0.75, 95 % CI 0.56–0.97, p = 0.02; mortality HR 0.61, 95 % CI 0.43–0.87, p = 0.005) |
Rothwell et al. (2011) [7] | 8 | 75< | Any | Regular aspirin use reduced cancer-related death (OR 0.79, 95 % CI 0.68–0.92, p = 0.003). Therapeutic effects increased with duration of aspirin use |
Rothwell et al. (2012) [17] | 5 | 75< | Any | Regular aspirin use reduced the risk of distant metastasis (HR 0.64, 95 % CI 0.48–0.84, p = 0.001) |